As doctors and nurses around the world work tirelessly to care for those affected by  COVID-19, there are many other healthcare professionals actively searching for a cure –  some of whom are in Nashville’s own backyard at Vanderbilt University Medical Center.  

Many people associate Ebola with the previous viral epidemic of the last decade, but, especially in light of the current global SARS-CoV-2 pandemic, few are aware that there is currently an active outbreak occurring in the Democratic Republic of the Congo. This deadly virus continues to wreak havoc in Africa, where containment of the virus fluctuates as new cases are reported.

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19. Researchers from the Vanderbilt Vaccine Center (VVC) have rapidly responded to this outbreak by building a comprehensive “toolkit” to identify and analyze antibodies isolated from the blood of survivors for their ability to neutralize SARS-CoV-2, the virus that causes COVID-19.

Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center. “We are thrilled that Dr. Carnahan, who is an accomplished antibody scientist, has taken over this important leadership position in our rapidly expanding research center,” said center director James Crowe Jr., MD.

As a novel and dangerous coronavirus continues to sicken thousands in China and a few dozen others in countries around the world, including the United States, U.S. academic researchers and government experts are working around the clock to understand, treat, and help prevent further spread of this emerging viral threat. “We are already functioning as if there is a worldwide pandemic,” says James Crowe, Jr., MD, an immunologist at Vanderbilt University School of Medicine and director of the Vanderbilt Vaccine Center.

Asian lineage avian influenza virus (H7N9) is a subtype of influenza virus that can infect humans following exposure to live, infected poultry. There have been several outbreaks since the first reported case in China in 2013, and the mortality rate is as high as 39 percent. Although person-to-person transmission of the virus is unlikely, influenza viruses are constantly evolving into new strains. Therefore, there is a constant threat of emergence of more pathogenic and resistant viruses with the ability to trigger a worldwide pandemic outbreak.